United States Patent 9,750,684 Scope and Claims Analysis: Topical Ophthalmic Cetirizine Formulation (0.1% to 0.25%)
Patent 9,750,684 is a formulation-only US patent that claims a topical ophthalmic vehicle plus narrow compositional and functional constraints. The independent claim (claim 1) is limited to: (i) cetirizine as the only active agent, (ii) a specific cetirizine concentration band (0.1% to 0.25% w/v), (iii) a fixed excipient package and ranges (PEG 400, dibasic sodium phosphate, hypromellose, polysorbate 80, glycerin band, edetate disodium, benzalkonium chloride, purified water), (iv) a pH of 7, and (v) explicit exclusion of cyclodextrins or other solubilizing compounds. Dependent claims narrow to 0.1% cetirizine (claim 2) and a specific glycerin level within the vehicle (claim 3), and then lock the cetirizine salt form (claim 4).
Practical claim scope outcome: the estate is best read as protecting a specific vehicle architecture for cetirizine ophthalmic delivery rather than the general concept of cetirizine eye drops.
What exactly is patented in US 9,750,684: cetirizine-only topical ophthalmic formulation with fixed excipient vehicle?
Claim 1: “topical ophthalmic formulation” defined by active-only limitation plus vehicle + pH + solubilizer exclusion
Claim 1 requires all of the following (each is an eligibility element that must be met for infringement):
A. Dosage form / intended use
- “Topical ophthalmic formulation” (eye drop-like formulation; no device claim, no method-of-use claim).
B. Active ingredient limitation
- Cetirizine hydrochloride or dihydrochloride
- Cetirizine is the only active agent in the formulation
Scope impact: this excludes any combination with another pharmacologically active ingredient (examples conceptually: antihistamine plus mast-cell stabilizer, antihistamine plus decongestant, steroid, NSAID, etc.). Combination products are outside the claim unless the second “active” is argued to be non-active (but the claim language is tight).
C. Cetirizine concentration band
- 0.1% to 0.25% (w/v) cetirizine (salt form as above).
D. Vehicle composition is constrained
The claim locks in a multi-excipient system with set values (and one range):
- 1% Polyethylene glycol 400 (PEG 400), NF
- 0.2% dibasic sodium phosphate, anhydrous, USP
- 0.25% hypromellose, USP
- 0.1% Polysorbate 80, NF
- 1.2% to 1.8% glycerin, USP
- 0.025% edetate disodium, USP
- 0.01% benzalkonium chloride (BAC), NF
- purified water, USP (q.s. to volume)
- pH 7 (functional parameter as required)
E. Explicit negative limitation about solubilizers
- “does not contain a cyclodextrin or other solubilizing compound.”
Scope impact: the formulation must avoid cyclodextrins (common solubilizers for hydrophobic APIs) and also avoid “other solubilizing compounds,” which is broader than just cyclodextrins. This phrase can matter heavily in design-around: even if cyclodextrin is absent, adding a different solubilizer could take the product outside the literal claim.
Claim 1 scope statement (featured-snippet ready)
US 9,750,684 claim 1 covers ophthalmic cetirizine (0.1% to 0.25% w/v) as the only active, in a vehicle of 1% PEG 400, 0.2% anhydrous dibasic sodium phosphate, 0.25% hypromellose, 0.1% polysorbate 80, 1.2%–1.8% glycerin, 0.025% edetate disodium, 0.01% benzalkonium chloride, purified water, with pH 7, excluding cyclodextrins or other solubilizing compounds.
How narrow are the dependent claims: what does claim 2, claim 3, and claim 4 add beyond claim 1?
Claim 2: locks cetirizine at 0.1%
- Independent claim 1 band is 0.1% to 0.25%.
- Claim 2 adds: cetirizine concentration = 0.1% (w/v).
Scope impact: claim 2 carves out a lower-concentration subset within claim 1. If a product uses 0.2% or 0.25%, claim 2 does not read on it.
Claim 3: “consisting essentially of” with a specific glycerin level (1.8%)
Claim 3 changes the vehicle constraint using “consisting essentially of,” which imports a different interpretation than “comprising”:
- Formulation consisting essentially of the listed components and no other ingredients that would materially affect the basic and novel characteristics.
- Sets glycerin at 1.8% (top of claim 1 range).
- Otherwise it restates the same vehicle components and pH 7 and solubilizer exclusion.
Scope impact:
- It narrows to the 1.8% glycerin embodiment.
- “Consisting essentially of” leaves room for immaterial add-ins, but it still limits the field versus a pure open-ended composition. A challenger typically attacks “materially affect” concepts in claim interpretation.
Claim 4: locks cetirizine salt identity
- Dependent on claim 3, it adds: cetirizine is present as cetirizine hydrochloride or dihydrochloride (salt form explicitly restated).
Scope impact: claim 4 is a further narrowing within the already salt-limited claim 1. In practice it often reinforces that only those salts qualify.
Does US 9,750,684 cover combination eye drops or only cetirizine monotherapy?
The “cetirizine is the only active agent” limitation likely bars combination products
Claim 1’s express “only active agent” constraint is a hard exclusion. A formulation containing:
- additional therapeutic actives, or
- another agent that qualifies as an “active” pharmacological ingredient
would not meet the claim.
Design-around path: a competitor seeking to enter with a combination product would likely avoid literal infringement by including a second active, assuming the second ingredient is clearly active under regulatory and scientific characterization.
Which formulation elements are the main infringement drivers: pH 7, PEG 400, BAC, hypromellose, polysorbate 80, glycerin range, and solubilizer exclusion?
pH 7 is a required parameter
Claim 1 requires pH 7. A competitor could attempt to shift to a slightly different pH. But infringement can turn on claim construction of “pH 7” in manufacturing tolerances. The claim is explicit, so pH-shift is a key lever.
Solubilizer exclusion is an additional barrier
The claim requires the formulation does not contain a cyclodextrin or other solubilizing compound. That is broader than a single excipient exclusion.
Implication: products formulated with:
- cyclodextrin inclusion complexes, or
- other solubilizing excipients argued to be “solubilizing compounds”
can be outside the claim. However, “other solubilizing compound” is fact-intensive and may invite disputes about classification of excipients.
Fixed vehicle excipient package reduces “workaround” freedom
Most excipients are fixed at single values, not ranges (PEG 400 at 1%, dibasic sodium phosphate at 0.2%, hypromellose at 0.25%, polysorbate 80 at 0.1%, edetate disodium at 0.025%, BAC at 0.01%). Only glycerin is a range (1.2% to 1.8%), and cetirizine concentration is a band.
What patents protect cetirizine ophthalmic topical formulations around US 9,750,684? (Landscape map focused on vehicle-formulation design space)
Scope-based landscape inference (based on claim architecture):
A claim like this typically sits in a cluster where other patents protect:
- other cetirizine ophthalmic concentrations,
- alternative vehicle systems (different polymers, surfactants, osmolarity adjusters),
- pH or buffer systems,
- preservatives (BAC alternatives),
- cyclodextrin inclusion complexes or other solubilizer systems,
- prodrugs or different cetirizine salt forms,
- method-of-use claims (even if this patent is formulation-focused).
But a legally actionable “patent landscape” requires citation-level data (patent numbers, assignees, claims, and expiration dates). No patent family list or Orange Book mapping was provided for this matter, and the user request does not include the underlying drug name tied to US 9,750,684.
Accordingly, no enumerated competitor patent list can be produced without inventing data.
When does US 9,750,684 lose exclusivity in the US? (Expiration and exclusivity timing framework)
US 9,750,684 is a US patent number, but the filing date, priority date, and any patent term adjustment or terminal disclaimer terms are not provided. Under US law, term generally tracks:
- 20 years from the earliest non-provisional effective filing date, adjusted for PTA/terminal disclaimers.
No precise expiration date can be stated without the priority/filing dates and any adjustments. Therefore no exclusivity timeline is provided.
What Orange Book status does US 9,750,684 have for cetirizine ophthalmic products?
Orange Book status depends on:
- the specific FDA product (listed drug),
- the submission number,
- and which patents are listed for that NDA/ANDA/BLA.
The request provides the patent claims but does not identify the FDA product(s) or the Orange Book entry. No Orange Book mapping can be correctly asserted without product-level identifiers.
What generic entry risks exist if a Paragraph IV ANDA targets the same vehicle?
Literal infringement risk is high if the ANDA matches claim 1’s vehicle and pH
A generic entering with:
- cetirizine monotherapy,
- 0.1% to 0.25% concentration,
- the same excipient package,
- pH 7,
- and no cyclodextrin or other solubilizer
creates the highest literal infringement risk.
Where Paragraph IV applicants often attack
Common non-infringement strategies against this kind of claim architecture include:
- shifting pH away from 7,
- modifying excipient levels (especially glycerin if the product aims for claim 3 specifically),
- replacing PEG 400 or polysorbate 80 with different surfactant systems,
- altering preservative strategy (BAC vs alternatives),
- introducing a solubilizer/excipient that is argued to be outside “no solubilizing compound,” or eliminating the specific solubilization characteristics relied on by the claim.
However, the exact viable design-around set depends on the ANDA formulation composition and claim construction. Without the ANDA or comparative product specs, no actionable probability ranking can be produced.
How does US 9,750,684 compare with typical cetirizine ophthalmic formulation patent claim strategies?
This patent’s strategy is “vehicle lock + negative solubilizer limitation”
Compared with broader claims, this patent has:
- explicit “only active agent” constraint,
- a tight set of excipients at fixed levels,
- a pH requirement,
- and an exclusion of cyclodextrins and “other solubilizing compound.”
Competitor patents are likely broader elsewhere
In practice, competitors often pursue:
- different polymer/surfactant systems,
- different buffering systems,
- different pH targets,
- or solubilizer-inclusive formulations (if cetirizine solubility or stability drives that approach).
That is consistent with how the claim carves out a narrow safe harbor: it is hard to avoid without changing core vehicle and/or pH and/or solubilizer content.
Key Takeaways
- US 9,750,684 is a formulation-only US patent for topical ophthalmic cetirizine.
- Claim 1 is narrow: cetirizine monotherapy; 0.1% to 0.25% cetirizine; a specific excipient vehicle (PEG 400 1%, dibasic sodium phosphate 0.2%, hypromellose 0.25%, polysorbate 80 0.1%, glycerin 1.2% to 1.8%, edetate disodium 0.025%, BAC 0.01%, purified water); pH 7; and no cyclodextrin or other solubilizing compound.
- Claim 2 narrows to 0.1% cetirizine.
- Claim 3 further narrows to a “consisting essentially of” embodiment with glycerin at 1.8%.
- Claim 4 confirms cetirizine salt identity (hydrochloride or dihydrochloride) for the claim 3 embodiment.
- Literal infringement risk is highest for products matching the exact vehicle, pH, and solubilizer exclusions.
FAQs
-
What does “cetirizine is the only active agent” exclude in ophthalmic formulations?
Any additional therapeutic active ingredients, assuming they qualify as “active” pharmacologic agents.
-
How does the “pH 7” limitation affect formulation design?
It requires the product’s measured formulation pH to be at the claimed value, limiting straightforward tolerance-based differences.
-
Why is the “does not contain a cyclodextrin or other solubilizing compound” limitation strategically important?
It bars both cyclodextrins and potentially other solubilizing excipients, tightening design-around options.
-
Does changing glycerin concentration avoid infringement of claim 3 but not claim 1?
Claim 3 targets glycerin at 1.8%; claim 1 covers 1.2% to 1.8%, so changes must move outside the relevant range to avoid either claim.
-
Is US 9,750,684 limited to cetirizine hydrochloride and dihydrochloride salts?
The claims specify cetirizine hydrochloride or dihydrochloride, and those salt forms are required.
References
- United States Patent 9,750,684 (claims as provided in the prompt).
